Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Leukemia

• Publication date

  2015-06-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2015.151PMID 26088953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevated plasma 2‐hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment

  2014cited by this paper
• Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

  2014cited by this paper
• Quantification of rare NPM1 mutation subtypes by digital PCR

  2014cited by this paper
• AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

  2014cited by this paper
• Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

  2012cited by this paper
• Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

  2011cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride.

  2004cited by this paper

• Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict IDH mutation in acute myeloid leukemia

  2023cites this paper
• A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors

  2021cites this paper
• Emerging pharmacotherapies for elderly acute myeloid leukemia patients

  2020cites this paper
• The role of IDH mutations in acute myeloid leukemia.

  2018cites this paper
• Methods of Detection of Measurable Residual Disease in AML

  2017cites this paper
• Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory.

  2017cites this paper
• Nanofluidic Allele-Specific Digital PCR Method for Quantifying IDH1 and IDH2 Mutation Burden in Acute Myeloid Leukemia.

  2017cites this paper
• Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.

  2016cites this paper
• Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia

  2016cites this paper